Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases

NCT ID: NCT00003324

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-12-31

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells in a single high dose. Combining radiation therapy with surgery may be a more effective treatment for brain metastases.

PURPOSE: Clinical trial to study the effectiveness of radiation therapy with or without surgery in treating patients who have brain metastases.

Detailed Description

OBJECTIVES:

• Develop prognostic factors for patients with brain metastases treated by focal treatment without concurrent whole brain irradiation.
• Determine whether focal treatment without whole brain radiotherapy produces good long-term outcome in patients with four or less cerebral metastases.
• Assess survival, physical and cognitive functioning, and quality of life of patients treated on this protocol.

OUTLINE: Quality of life is assessed using the FACT-BR scale, physical function is assessed using the FIM scale, and cognition is assessed using two brief pencil and paper tests.

Patients receive focal therapy for cerebral metastases by any combination of (1) surgery plus fractionated stereotactic radiotherapy to surgical bed, or (2) single fraction stereotactic radiotherapy by linear accelerator with or without a radiation sensitizer.

Patients are followed at 2 and 10 weeks, then every 3 months for 18 months, then every 6 months for 3 years, then annually. Quality of life is assessed at each followup visit.

Patients suffering intracerebral relapse are offered further focal therapy if they have no more than 3 metastases, no more than 6 lesions over consecutive scans, and continue to have life expectancy of at least 3 months and Karnofsky performance status of 60-100%. Otherwise, relapsed patients are offered whole brain radiotherapy or supportive treatment with steroids, and may also receive stereotactic boost to the new lesions. Patients who have received prior whole brain irradiation will be offered entry into other protocols if eligible or supportive treatment with steroids. Patients are followed as above.

PROJECTED ACCRUAL: At least 60 patients will be enrolled in this study.

Conditions

Metastatic Cancer

Study Design

• Primary Study Purpose: TREATMENT

Interventions

conventional surgery

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Biopsy, CT scan, or MRI proven cerebral metastases with known current or previous systemic malignancy OR
• Biopsy proven cerebral metastases other than from small cell lung cancer or lymphoma
• Refused whole brain radiation therapy OR
• Received prior whole brain radiation therapy and ineligible for other relapse protocols
• 18 and over
• Karnofsky 60-100%
• Life expectancy:At least 3 months
• Concurrent steroids allowed

Exclusion Criteria

• more than four cerebral metastases on MRI scan and suitable for focal treatment with surgery and/or stereotactic radiotherapy with a linear accelerator
• more than 2 weeks since prior focal radiation
• more than 2 weeks since prior focal surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Judith M. Ford, MD, PhD

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Countries

United States

References

Chitapanarux I, Goss B, Vongtama R, Frighetto L, De Salles A, Selch M, Duick M, Solberg T, Wallace R, Cabatan-Awang C, Ford J. Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy. J Neurooncol. 2003 Jan;61(2):143-9. doi: 10.1023/a:1022173922312.

Reference Type: RESULT

PMID: 12622453 (View on PubMed)

Other Identifiers

UCLA-HSPC-9710074

Identifier Type: -

Identifier Source: secondary_id

UCLA-HSPC-971007401

Identifier Type: -

Identifier Source: secondary_id

NCI-G98-1417

Identifier Type: -

Identifier Source: secondary_id

CDR0000066275

Identifier Type: -

Identifier Source: org_study_id